Purpose: In 1987 the Italian Cooperative Group for the Study of hairy cell leukemia (HCL) started a prospective trial with the following three major aims: 1) to confirm the effectiveness of alpha-IFN as first-line treatment; 2) to assess the usefulness of splenectomy as consolidation treatment in patients achieving a satisfactory partial remission (PR) with alpha-IFN, and 3) to explore whether splenectomy in patients achieving complete remission (CR) with alpha-IFN can reduce the risk of relapse after discontinuation of the drug. Patients and Methods: One-hundred seventy-seven patients with histologically-confirmed HCL were registered in the HCL88-A trial between December 1987 and January 1992. Inclusion criteria included no previous treatment and age less than 66 years. All patients received total doses of 3 MU of alpha-IFN daily for 12 months except for those who achieved early CR and would stop treatment after 6 or 9 months. Patients could be treated with different alpha-IFNs. At the time of the present analysis, 166 patients (93.8%) were fully evaluable. Results: Treatment of HCL patients with alpha-IFN at the onset of the disease resulted in 28 CR (16.9%), 103 PR (62.0%), and 27 Minor Remissions (MR) (16.3%). Patients treated with different alpha-IFNs achieved similar results: the overall response rate (CR + PR + MR) was 92.7%, 97.2%, and 95.3% for patients treated with r-alpha-2a, r-alpha2b, and alpha-N1, respectively. The presence of a leukemic phase and a poor performance status were associated with a statistically significant lower response rate. Patients who were randomly assigned and underwent splenectomy after achieving a PR had a better but not significant 4-year progression-free survival than cases randomized for observation (53% vs. 22%, p = 0.116). Overall, 5 patients died after study entry, with an actuarial 5-year survival rate of 96% for the entire group of 166 patients. After a mean follow-up time of 38 months, only one second malignancy has been recorded. Conclusions: Initial therapy with alpha-IFN, regardless of the type of alpha-IFN used, induces satisfactory responses in the majority of patients with HCL, but in most instances discontinuation of treatment results in recurrence of disease. In most cases alpha-IFN improves the performance status of patients and favors a satisfactory bone marrow recovery and thus could still play a role in the initial management of the disease. Although splenectomy following alpha-IFN could prolong the progression free survival, its use should be restricted to selected cases.
|Data di pubblicazione:||1994|
|Titolo:||Long term results of alpha interferon as initial therapy and splenectomy as consolidation therapy in patients with hairy cell leukemia. Final report from the Italian cooperative group for HCL|
|Autore/i:||Federico, Massimo; A., Frassoldati; T., Lamparelli; R., Foa; M., Brugiatelli; L., Annino; L., Baldini; G., Capnist; T., Chisesi; Pf, Dicelle; R., Invernizzi; F., Lauria; M., Truini; L., Resegotti; Silingardi, Vittorio; Ee, Damasio|
|Codice identificativo ISI:||WOS:A1994PM78600013|
|Codice identificativo Scopus:||2-s2.0-0027964526|
|Codice identificativo Pubmed:||7826905|
|Citazione:||Long term results of alpha interferon as initial therapy and splenectomy as consolidation therapy in patients with hairy cell leukemia. Final report from the Italian cooperative group for HCL / M. FEDERICO; A. FRASSOLDATI; T. LAMPARELLI; R. FOA; M. BRUGIATELLI; L. ANNINO; L. BALDINI; G. CAPNIST; T. CHISESI; PF DICELLE; R. INVERNIZZI; F. LAURIA; M. TRUINI; L. RESEGOTTI; V. SILINGARDI; EE DAMASIO. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - STAMPA. - 5(1994), pp. 725-731.|
|Tipologia||Articolo su rivista|
I documenti presenti in Iris Unimore sono rilasciati con licenza Creative Commons Attribuzione - Non commerciale - Non opere derivate 3.0 Italia, salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris